The inhibition of tau abnormality has been considered to be one of the most promising therapeutic approaches to AD, since pathological aggregation has been correlated with the hyperphosphorylation of microtubule-associated protein (MAP)-Tau in neurons and microglia. This evidence concerns the gene MAPT and Alzheimer disease.